Laparoscopic surgery for colorectal cancer
When compared to traditional open surgery, the recovery from a laparoscopic colectomy can be shorter and less uncomfortable.
What is laparoscopic surgery?
Laparoscopic surgery is a type of minimally invasive surgery. Instead of one large incision, the surgeon makes a few very small incisions (about ¼ to ½ inch) into the abdomen to insert a small surgical camera and instruments. A slightly bigger incision, about two inches wide, is made to remove the tumor and any other tissue.


Why have laparoscopic surgery?
Advantages to laparoscopic surgery versus open procedures include:
- Less recovery time
- Lower risk of infection
- Smaller scars
- Less pain and discomfort after surgery
- Shorter hospital stay
Speedier return to normal activities
Who is eligible for a laparoscopic colectomy?
Many colorectal cancer patients are good candidates for laparoscopic colectomy surgery.
The best option for you depends on several factors, including:
- your overall health
- your medical history
- your surgeon’s experience
- the cancer stage
- the cancer location
What happens during a laparoscopic surgery?
- Carbon dioxide gas is used to inflate the abdomen and create space for the surgeon to operate.
- The laparoscope (a small camera) sends video images from inside the body to monitors in the operating room.
- During the procedure, the surgeon moves the instruments by watching the monitors.
- The surgeon will remove the segment of the colon or rectum that contains the tumor through the larger incision.
Brittany's story: open versus laparoscopic surgery for colorectal cancer
This short video tells the story of Colorado resident Brittany Slater, whose life was turned upside-down by a colon cancer diagnosis at age 23. Her tale demonstrates the differences between an open procedure and a laparoscopic surgery.

Up Next
More about surgery optionsTop resources

2025 ASCO update: Six big studies
The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.

NIH: Combination immunotherapy shrank GI cancers
A new kind of tumor infiltrating lymphocyte (TIL) therapy improved the treatment’s effectiveness in patients with metastatic GI cancers.

Lexie Haglund: Beating stage IV CRC
Discover how knowing her G12C biomarker guided Lexie’s stage IV colorectal cancer treatment — from a shock diagnosis to HIPEC surgery — and why screening, research, and self-advocacy matter.